Our Product
Our company is developing a clinical-stage PLUS CAR-T cell product pipeline for solid tumors. We are working with clinicians and key opinion leaders in Japan and the United States to develop our product candidates. We have partnered with the top-tier Chulalongkorn Hospital in Thailand and the Cell & Gene Therapy Manufacture Center to ensure our innovative pipeline product candidates undergo safety and efficacy testing per international standards. We have generated all our product candidates internally and our pipeline diagram below showcases our most advanced product candidates.
CAR T cell therapy has exhibited remarkable success in treating certain blood cancers; however, its efficacy in solid tumor treatment is constrained by several challenges. Unlike blood cancers, solid tumors present a complex microenvironment that hinders CAR T cells' infiltration, persistence, and activity. The lack of specific tumor antigens exclusive to cancer cells further complicates targeting, often leading to unintended damage to healthy tissues. Additionally, the immunosuppressive nature of the tumor microenvironment dampens CAR T cell function, limiting their therapeutic impact. Overcoming these hurdles remains a critical endeavour in harnessing CAR T cell therapy's full potential for effective solid tumor treatment
PLUS CAR technology
Our innovation lies in a novel endosignaling domain with proprietary enhancers that provide unique T cell stimulation, propelling the potency and persistence of CAR T cells beyond conventional design. In preclinical models, our pioneering CAR T cells have showcased remarkable antitumor activity compared to conventional methods. These cells demonstrate heightened tumor eradication, signaling a potential breakthrough in cancer treatment efficacy
Key features
We have incorporated our proprietary endodomain into second-generation CAR constructs,
which provides a substantial enhancement
to cellular proliferation, cytotoxicity, and
persistence while mitigating exhaustion
in CAR T cells targeted toward solid
tumors. Furthermore, our CAR T cell
platform demonstrates a unique
capability to effectively target multiple
types of solid tumors. These advancements
underline the potential for a significant shift
in the landscape of solid tumor therapy
